Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.
J. Ichante
No relevant relationships to disclose
A. Adenis
No relevant relationships to disclose
D. Malka
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
E. Francois
Consultant or Advisory Role - Roche
Honoraria - Roche
E. Boucher
No relevant relationships to disclose
B. Chauffert
No relevant relationships to disclose
J. Pignon
No relevant relationships to disclose
M. Ychou
Consultant or Advisory Role - Roche
Honoraria - Roche
J. Pierga
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
C. Montoto-Grillot
No relevant relationships to disclose
T. Conroy
Research Funding - Roche
M. Ducreux
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche